Uncategorized

New Taiho, Cullian data heats up lung cancer drug battle

Published

on

The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version